Fate Therapeutics (FATE) Net Cash Flow (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Net Cash Flow data on file, last reported at -$7.2 million in Q1 2026.

• Quarterly Net Cash Flow fell 181.62% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.5 million (up 93.21% YoY) and the FY2025 annual result came in at $10.6 million, up 198.22% from the prior year.
• Net Cash Flow fell to -$7.2 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $79.5 million in Q1 2024 to a low of -$84.4 million in Q2 2024.
• A 5-year average of -$5.8 million and a median of -$3.7 million in 2025 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 511.39% in 2024, down 1883.71% in 2024.
• Tracing FATE's Net Cash Flow over 5 years: stood at -$20.8 million in 2022, then jumped by 141.12% to $8.5 million in 2023, then plunged by 121.71% to -$1.9 million in 2024, then jumped by 424.12% to $6.0 million in 2025, then slumped by 220.46% to -$7.2 million in 2026.
• The last three Net Cash Flow figures came in at -$7.2 million (Q1 2026), $6.0 million (Q4 2025), and -$627000.0 (Q3 2025), per Business Quant data.